Accentia Biopharmaceuticals, Inc. (Accentia) is a biopharmaceutical company focused on the development and commercialization of late-stage, targeted therapeutic clinical products in the areas of respiratory disease and oncology. The Company operates in two segments: Biopharmaceutical Products and Services, and Specialty Pharmaceuticals. The Biopharmaceutical Products and Services segment develops late-stage biopharmaceutical products with an emphasis on the respiratory and oncology therapeutic areas. The products developed in this segment are SinuNase, BiovaxID and Revimmune. This segment also includes the Company’s consulting business, which provides a range of services relating to biopharmaceutical product development, and its biologics products business. The Specialty Pharmaceuticals segment markets and sells pharmaceutical products that are developed primarily by its third-party development partners. In this segment, Accentia sells the Respi~TANN, SinuTest and Zinotic.

GlaxoSmithKline plc company was founded in 1935 and is based in Brentford, the United Kingdom. GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health related consumer products. The company offers prescription medicines to treat a range of conditions, such as infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer. It also markets approximately 25 vaccines to prevent life-threatening or crippling illnesses, such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza, and bacterial meningitis. In addition, the company offers OTC medicines, such as alli, a weight loss medicine; Panadol, a paracetamol/acetaminophen analgesic; smoking control products under the NicoDerm, NiQuitin CQ, Nicabate, and Nicorette names; and other brands, including Breathe Right nasal strips and Tums. Its oral healthcare products primarily comprise Aquafresh, a range of toothpastes, toothbrushes, and mouthwashes; Sensodyne, a range of toothpastes and toothbrushes, including Pronamel to protect from acid erosion; Biotene, a treatment for dry mouth; and Polident, PoliGrip, and Corega, which are denture care cleansers and adhesives. Further, the company provides nutritional healthcare products, such as Lucozade, a range of energy and sports drinks; Horlicks, a range of milk-based malted food and chocolate drinks; and Ribena, a blackcurrant juice-based drink. GlaxoSmithKline operates in Europe, North America, Central and South America, the Caribbean, Asia, Australia, the Middle East, Africa, and the Southeast Asia.

Oxford BioMedica has no reservations about launching attacks on disease. The biotechnology company focuses on developing gene therapy treatments for oncology and neurotherapy. Its lead product,TroVax, is in testing for renal and colorectal cancer and is designed to stimulate the body's immune response to attack tumor cells. Another leading candidate, ProSavin, is in testing for treatment of Parkinson's disease. The company has several additional products in various stages of clinical development. Oxford BioMedica has awarded Sanofi-Aventis exclusive rights to develop and commercialize TroVax globally. The company's California-based BioMedica subsidiary handles its business development in North America and Asia.

Ambrilia Biopharma likes to work with drug candidates when they're still in the early stages of development. Once they hit late stage, the company prefers to license them out for further development. The company is also working to manufacture better formulations of existing drugs to bring in cash. Ambrilia's pipeline includes anti-virals and a handful of oncology drug candidates including generic candidates Octreotide and Goserelin. While it is shifting its focus onto anti-viral drugs, the company is continuing with clinical trials of the two oncology drugs. Mid-shift, however, the company's funds dried up and it filed for bankruptcy protection in the Canadian courts.

Since its inception in 1740, Whatman knows what it takes to separate the wheat from the chaff. Whatman company makes filters, membranes, and specialty products for applications in the analytical, health care, and bioscience markets in some 70 countries. Whatman company's products can be found in medical devices and diagnostic testing kits. Whatman has also developed technology for the isolation, transportation, storage, and purification of DNA for gathering genetic information. Whatman makes other products such as blotting papers, syringe filters, and chromatography products. Whatman company was acquired by GE Healthcare in 2008.

Osiris Therapeutics, Inc. company was founded in 1992 and is headquartered in Columbia, Maryland. Osiris Therapeutics, Inc., a stem cell therapeutic company, develops products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas in the United States. The company's principal product includes Prochymal, which is in phase III clinical trials for the treatment of steroid refractory Graft versus Host Disease (GvHD), acute GvHD, Crohn's disease, and acute radiation syndrome; and in phase II clinical trials for the treatment of Type I diabetes mellitus, acute myocardial infarction, and chronic obstructive pulmonary disease. Its product also consists of Chondrogen, a Phase II clinical trial product for the treatment of osteoarthritis and the reduction of pain in the knee. Osiris Therapeutics has collaboration agreements with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen; Juvenile Diabetes Research Foundation for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes; and JCR Pharmaceuticals Co., Ltd. for distributing Prochymal for the treatment of GvHD in Japan.

Anika Therapeutics, Inc. company was founded in 1983 and is headquartered in Bedford, Massachusetts. Anika Therapeutics, Inc. develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair. Its products are based on hyaluronic acid (HA), a naturally occurring biocompatible polymer found in the body. The company offers ORTHOVISC, an HA product used in the treatment of some forms of osteoarthritis in humans; and AMVISC, AMVISC Plus, STAARVISC-II, and ShellGel that are injectable ophthalmic viscoelastic HA products used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation. It also provides HYVISC, an HA product used in the treatment of equine osteoarthritis; INCERT, an HA based anti-adhesive for surgical applications; and ORTHOVISC mini, a treatment for osteoarthritis targeting small joints. In addition, the company offers MONOVISC, a single-injection osteoarthritis product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine osteoarthritis; and ELEVESS, which is designed as a family of aesthetic dermatology products for facial wrinkles, scar remediation, and lip augmentation. Further, it involves in the research and development of joint health related products, such as a single-injection treatment product that uses a non-animal source HA. Anika Therapeutics, Inc. offers its products in the United States, as well as in Canada, Europe, Turkey, the Middle East, and Asia through representatives, agents, and distributors.

For biotechnology and pharmaceutical companies whose next big breakthrough is stuck in the test tube, Oxford Therapeutics Consulting could have the answer. The product development consulting firm offers strategic planning and product management for biotechs and pharmas that are short on staff and experience in bringing a new product through the lengthy development pipeline. Oxford Therapeutics' team of consultants work primarily with smaller companies on products such as anticancer agents, antibacterial and antiviral compounds, and therapeutic vaccines.

Virbac Corporation makes animal health and pet-care products and sells them to veterinarians and retailers. For dogs and cats it makes C.E.T dental products, Allederm dermatological products, and digestive and hairball remedies. The company's Iverhart medication prevents heartworms in dogs. Virbac also makes antibiotics, dewormer, and euthanasia products. Its other brands include Biomox, Clintabs, and Vetasyl. In addition to producing its own animal health products, the company provides contract manufacturing through subsidiary PM Resources. The company is owned by Virbac SA.

Cardium Therapeutics, Inc. (Cardium) is a medical technology development-stage company. The Company is primarily focused on the development, manufacture and sale of therapeutic products and devices for cardiovascular, ischemic and related indications. Cardium owns a portfolio of biologic growth factors and related delivery techniques, acquired from the Schering AG Group, for potential use in treating ischemic and other cardiovascular conditions. Cardium owns rights to the assets and technologies of Tissue Repair Company, a company focused on the development of growth factor therapeutics for the potential treatment of tissue wounds, such as chronic diabetic wounds. Tissue Repair Company is operated as a wholly owned subsidiary of Cardium. In July 2009, the Company completed the asset sale of its InnerCool Therapies business to Koninklijke Philips Electronics NV.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.